



POSTER PRESENTATION

Open Access

Active regulatory T-cells contribute to broadened T-cell repertoire diversity in ivIg-treated SLE patients

Nuno Costa^{1*}, Ana E Pires², Ana M Gabriel¹, Luiz F Goulart¹, Clara Pereira^{1,3}, Barbara Leal³, Ana C Queiros², Wahiba Chaaara⁴, Maria F Moraes-Fontes^{1,6}, Carlos Vasconcelos⁵, Carlos Ferreira⁶, Jorge Martins⁷, Marina Bastos⁸, Maria J Santos⁹, Maria A Pereira¹⁰, Berta Martins³, Margarida Lima⁵, Cristina João², Adrien Six⁴, Jocelyne Demengeot¹, Constantin Fesel¹

From 6th European Workshop on Immune-Mediated Inflammatory Diseases
Nice, France. 23-25 November 2011

Intravenous IgG (ivIg) is a therapeutic alternative for lupus erythematosus. Relative oligoclonality of circulating T-cells in SLE has been reported. Also CD4+Foxp3+ regulatory T-cells (Tregs) have a characteristically reduced activity in SLE, reflected by CD25 surface density. Aiming to study the role of Tregs for ivIg therapy, we characterized Tregs and determined TCR spectratypes of four Vb families with reported oligoclonality, in 15 lupus patients (14 with SLE and one with discoid LE) treated with ivIg in cycles of 2-6 consecutive monthly infusions. Among these 15 patients, 11 responded with clinical improvement. Cell counts, cytometry and TCR spectratypes were obtained from peripheral blood at various time points before, during and after ivIg treatment. T-cell oligoclonality was assessed as Vb-familywise repertoire perturbation, calculated for each patient in respect to an individual reference profile averaged over all available time points. For 11/15 patients, average Vb1/Vb2/Vb11/Vb14 repertoires were less perturbed under ivIg treatment than outside ivIg therapy. The four exceptions with relatively increased average perturbation during ivIg therapy included three patients who failed to respond clinically to an ivIg therapy cycle. Patients' Treg CD25 surface density (cytometric MFI) was, other than Treg/CD4+ frequency, clearly reduced when compared to healthy controls, but not obviously influenced by ivIg. However, patients' average Treg CD25 MFI was found negatively correlated with both Vb11 and Vb14 perturbations measured under ivIg therapy, which indicates a role of active Tregs in the therapeutic effect of ivIg.

Acknowledgements

This work was supported by Octapharma.

Author details

¹Instituto Gulbenkian de Ciência, Oeiras, Portugal. ²IPO-CIPM/CEDOC-FCM, Lisboa, Portugal. ³ICBAS, Porto, Portugal. ⁴UPMC-Paris-6/CNRS-UMR7211/AP-HP, Paris, France. ⁵Hospital Sto-António, Porto, Portugal. ⁶Hospital Sta-Maria, Lisboa, Portugal. ⁷Hospital Marmeleiros, Funchal, Portugal. ⁸Hospital São-Teotónio, Viseu, Portugal. ⁹Hospital Garcia de Orta, Almada, Portugal. ¹⁰Hospital de Faro, Faro, Portugal.

Published: 23 November 2011

doi:10.1186/1479-5876-9-S2-P6

Cite this article as: Costa et al.: Active regulatory T-cells contribute to broadened T-cell repertoire diversity in ivIg-treated SLE patients. *Journal of Translational Medicine* 2011 **9**(Suppl 2):P6.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Instituto Gulbenkian de Ciência, Oeiras, Portugal
Full list of author information is available at the end of the article